INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
The entire world has come major problem is facing on puberty womens for entier life cycle,involved in Common causes for Heay bleeding (periods) is termed is called-Menorrhagia , grappling with a common enemy in womens Menstrual cycles. The Heavy or prolonged vaginal bleeding.( HMB-Heavy Menstrual Bleeding) has menstrual period with excessively heavy blood flow.Abnormal utrine bleeding can be caused by strctural abnormalities in reproductive tract, anovulation, bleeding disorders, hormonal issues (hypothyroidism) or cancer of the reproductive tract.Tougher challenge leading to millions of cases and a staggering number of patients is affected in Anemic condition. Tranexamic Acid and Mefenamic Acid is an FDA-approved and sold under the oral administration for (NSAIDS and Antifibrinolytics) drug for use in Puberty womens for during heavy bleeding in menstrual cycle. Tranexamic Acid is a prevents the breakdown of blood clots to control excessive bleeding during periods. Mefenamic acid is also blocks the production of certain chemical messengers that cause pain and inflammation, Tranexamic acid blocks the activity one of the specific for preventing fibrin degradation , Tranexamic acid has a eight times the antifibrinolytic activity of an older analogue, aminocarproic acid. It is together Tranexamic Acid and Mefenamic acid is used for treatement of heavy menstrual bleeding and acute pain that occurs with menstrual disorders. According to the study conducted, it was found that when was given alone in the patient suffering from HMB with acute pain symptoms, the mean recovery was 87.3% and mortality rate was 69.34% Trapic-MF significantly reduces the heay and mortality and shows more safety,efficacy and reduced serious adverse effects by absolute 8% and no significant Grade 3 or 4 adverse effects were reported. When Tranexamic Acid was given in combination with Mefenamic acid was superior to Tranexamic acid alone in reducing recovery (65.5%) and accelerating improvement in clinical status among patients with heavy bleeding and pain, notably among those receiving problems. The mortality rate for Mefenamic acid in combination with Tranexamic acid , a relative reduction of 35%. Adverse events and serious adverse events were reported in 41% and 15% of patients treated with Mefenamic acid in combination with Tranexamic acid, respectively, vs. 48% and 20% in patients treated with Tranexamic acid.
"TRANEXAMIC ACID (TXA)- AND MEFENAMIC ACID: An Overview”,", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 4, page no.a594-a608, April-2023, Available :http://www.ijnrd.org/papers/IJNRD2304074.pdf
Downloads:
000118754
ISSN:
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Facebook Twitter Instagram LinkedIn